Literature DB >> 20039305

CD14-independent responses induced by a synthetic lipid A mimetic.

Amandine Legat1, Séverine Thomas, Philippe Hermand, Marcelle Van Mechelen, Michel Goldman, Dominique De Wit.   

Abstract

CRX-527 belongs to a new family of synthetic lipid A mimetics, the aminoalkyl glucosaminide 4-phosphates, which are considered as potential vaccine adjuvants or stand-alone immunotherapeutics to harness innate immune defenses. Since natural lipid A from bacterial LPS depends on membrane-bound (mCD14) or soluble CD14 for its TLR4 ligand activity, we investigated the involvement of both forms of CD14 in the responses elicited by CRX-527. First, we found that CRX-527 induces NF-kappaB and interferon regulatory factor-3 (IRF-3) activation in human embryonic kidney cells transfected with TLR4 and MD-2 genes alone, whereas the responses to LPS require either co-transfection of the gene encoding mCD14 or addition of soluble CD14. We then observed that monocyte-derived DC, which are devoid of mCD14 respond to CRX-527 but not to LPS in serum-free medium. Furthermore, we found that, in contrast to LPS, CRX-527 induces the production of cytokines in whole blood of a patient with paroxysmal nocturnal hemoglobinuria, a disease in which mCD14-dependent responses are defective. Finally, we demonstrated that splenocytes from CD14-deficient mice produce cytokines in response to CRX-527 but not to LPS. We conclude that the lipid A mimetic CRX-527 does not require the CD14 co-receptor to elicit TLR4-mediated responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20039305     DOI: 10.1002/eji.200939992

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.

Authors:  Miriam Canavese; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

2.  VEGF and LPS synergistically silence inflammatory response to Plasmodium berghei infection and protect against cerebral malaria.

Authors:  Miriam Canavese; Tania Dottorini; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

3.  The neonatal susceptibility window for inhalant allergen sensitization in the atopically predisposed canine asthma model.

Authors:  Christopher M Royer; Karin Rudolph; Edward G Barrett
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

4.  Brucella β 1,2 cyclic glucan is an activator of human and mouse dendritic cells.

Authors:  Anna Martirosyan; Camino Pérez-Gutierrez; Romain Banchereau; Hélène Dutartre; Patrick Lecine; Melissa Dullaers; Marielle Mello; Suzana Pinto Salcedo; Alexandre Muller; Lee Leserman; Yves Levy; Gerard Zurawski; Sandy Zurawski; Edgardo Moreno; Ignacio Moriyón; Eynav Klechevsky; Jacques Banchereau; Sangkon Oh; Jean-Pierre Gorvel
Journal:  PLoS Pathog       Date:  2012-11-15       Impact factor: 6.823

5.  Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface.

Authors:  Caroline Lonez; Kate L Irvine; Malvina Pizzuto; Boris I Schmidt; Nick J Gay; Jean-Marie Ruysschaert; Monique Gangloff; Clare E Bryant
Journal:  Cell Mol Life Sci       Date:  2015-05-09       Impact factor: 9.261

6.  TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection.

Authors:  Laure Perrin-Cocon; Anne Aublin-Gex; Stefania E Sestito; Kari Ann Shirey; Mira C Patel; Patrice André; Jorge C Blanco; Stefanie N Vogel; Francesco Peri; Vincent Lotteau
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

7.  CRX-527 induced differentiation of HSCs protecting the intestinal epithelium from radiation damage.

Authors:  Dongshu Liu; Suhe Dong; Cong Liu; Jicong Du; Sinian Wang; Huijie Yu; Wei Li; Zhongmin Chen; Renjun Peng; Qisheng Jiang; Mengying Zou; Fengsheng Li; Rong Zhang
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

Review 8.  TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.

Authors:  Allison M Owen; Jessica B Fults; Naeem K Patil; Antonio Hernandez; Julia K Bohannon
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.